Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study

Clinical trial NCT07264010 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07264010
Sponsor: Nanfang Hospital, Southern Medical University
Status: NOT_YET_RECRUITING
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Acute Myeloid Leukaemia (AML)Measurable Residual Disease (MRD)

Start date: 2025-12-01
Primary completion: 2026-12-30
Enrollment: 87

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.